



AAVBC

AMERICAN ACADEMY OF VALUE BASED CARE

Sickle Cell Anemia

Quick Reference Guide

2026

Table of Contents

1. CLINICAL SNAPSHOT	3
HCC/RAF V28 Mapping	4
2. RECOGNITION AND DIAGNOSIS	6
Medicare Part B Covered Screenings and Workup(Adult and Geriatric)	7
Subtle Early Signs in Older Adults (>65)	9
Adult Sickle Cell Disease: Lifespan Complications and Transition Risks	10
Diagnosis, Classification, and Diagnostic Thresholds	11
Clues to Dig Deeper	13
Common Oversights	14
Key Differentials in Elderly	15
Comorbidity Screening	16
3. MEAT DOCUMENTATION ESSENTIALS	18
Clinical Documentation Elements	19
Reframing Common Documentation Shortcuts	20
4. TREATMENT AND REFERRAL QUICK GUIDE	21
Therapy Escalation Criteria	22
Medication Safety in Elderly with SCD	24
When to Refer	26
Follow-Up Timing	27
Comorbidity Management — Primary Care Role	29
Cost-Smart Options	30
Patient Education and Adherence	32
Quality Metrics Tie-In	33
5. CODING REMINDERS AND CASE EXAMPLES	35
Coding Specificity	35
Annual Clinical Review and Confirmation	36
Good Documentation is Comprehensive Coding	37
Good Documentation — EHR Tips	38
Brief Case Examples	39
REFERENCES	40

1 CLINICAL SNAPSHOT

Definition: Sickle cell disease (SCD) is a group of inherited red blood cell disorders caused by autosomal-recessive mutations in the **HBB gene** that produce **abnormal hemoglobin S (HbS)**.^{1,2} Under deoxygenated conditions, **HbS polymerizes** into rigid rods that **distort red cells into a sickle shape**, reducing red cell lifespan from **120 days** to **10-20 days** and obstructing microvascular flow; this drives a cascade of vasculopathy, hemolytic anemia, acute pain crises, end-organ damage, and premature death.^{1,2} SCD is a **spectrum of genotype-defined disorders**: **HbSS** (sickle cell anemia, most severe), **HbS/β⁰-thalassemia** (functionally equivalent to HbSS), **HbSC** disease (generally milder but still causes significant complications), **HbS/β⁺-thalassemia** (variable severity), and rare variants **HbSD**, **HbSE**, and **HbSO-Arab**.^{2,3} **Sickle cell trait** (HbAS, one normal HBB allele) is a **carrier state, NOT active disease**.^{3,4}

ICD-10 Codes:

D57.x designates sickle-cell disorders, categorized by genotype, crisis status, and specific complication.⁵ Common codes: **D57.00** (HbSS with crisis, unspecified), **D57.01** (HbSS with acute chest syndrome (ACS) = **leading cause of SCD death**), **D57.02** (HbSS with splenic sequestration), **D57.03** (HbSS with cerebral vascular involvement), **D57.1** (sickle-cell disease without crisis; **genotype-nonspecific**), **D57.20** (HbSC without crisis), **D57.211** (HbSC with ACS), **D57.42** (HbS/β⁰-thal without crisis), **D57.44** (HbS/β⁺-thal without crisis), and **D57.3** (sickle-cell TRAIT; **carrier state only**). Complication codes paired alongside **D57**: **N18.x** (CKD), **I27.2x** (secondary pulmonary hypertension), **H35.x** (proliferative sickle retinopathy), **M87.x** (avascular necrosis), **F32.x** (depression).

Prevalence and Burden: SCD affects approximately **100,000 people** in the United States, predominantly **Black Americans (1 in 365 Black births)** and **Hispanic Americans (1 in 16,300 Hispanic births)**.^{6,7} More than 3 million Americans carry **sickle cell trait (D57.3)**.⁸ Life expectancy for publicly insured individuals with SCD is approximately **52.6 years**, roughly **20 years shorter** than the general population, meaning few patients historically survived to age 65.^{2,9} **Hydroxyurea therapy**, infection prophylaxis, and comprehensive care are now extending survival, with median survival increasing from age 14 years in 1973 to **as high as 61 years** in recent academic center cohorts, creating a growing but heavily comorbid Medicare-age SCD population.^{10,11} Adult Medicaid enrollees with SCD incur mean total costs of **\$45,114/year** vs. **\$6,039** for matched non-SCD adults (a 7.5-fold difference), driven primarily by hospitalizations (18.7-fold higher costs) and ED visits (12.7-fold higher costs).¹² Estimated lifetime medical costs reach **\$1.6-\$1.7 million** per patient.¹² Approximately **222,612 ED visits** per year are attributable to SCD nationally, three-fourths for **pain**.¹³ Medicare-specific PMPY data for adults aged 65+ are **essentially absent**: the Medicaid figures are the best available proxy, though the Jiao et al. nationwide cohort study of 94,616 Medicare and Medicaid beneficiaries demonstrated **significant survival disparities by insurance type** even among those reaching age ≥65.^{9,12}

AAVBC Knowledge Hub Premium Content Access

Continue reading your guide
with an AAVBC subscription

[Subscribe Now](#)

Already a subscriber? [Sign in](#)

Limited offer

Basic Membership Free

Includes access to downloadable Quick Reference Guides, mailing list for industry updates/medical information, research toolkits, AAVBC events and so much more!

Cancel at any time